Monographie - Palonosetron hydrochloride

Τελευταία ενημέρωση :
29/10/2024

Palonosetron hydrochloride

χημική δομή

Εμπορική ονομασία

Οι εμπορικές ονομασίες είναι ενδεικτικές και η σύνθεση των εκδόχων μπορεί να διαφέρει ανάλογα με τη χώρα και τα εργαστήρια

Aloxi	Αυστρία, Βέλγιο, Γερμανία, Δανία, Ελβετία, Ελλάδα, Η.Π.Α., Ιαπωνία, Ιρλανδία, Ισλανδία, Ισπανία, Ιταλία, Καναδάς, Λουξεμβούργο, Μαλαισία, Μεγάλη Βρετανία, Νορβηγία, Ολλανδία, Ουγγαρία, Πολωνία, Πορτογαλία, Ρουμανία, Σουηδία, Τουρκία, Φινλανδία
Chepatron	Ινδία
Cinvex	Τουρκία
Factoket	Μεξικό
Lotisa	Τουρκία
Onicit	Εκουαδόρ, Ιταλία, Κολομβία, Περού, Χιλή
Palohalt	Περού, Χιλή
Paloject	Τουρκία
Palonosetron	Βέλγιο, Γαλλία, Γερμανία, Εκουαδόρ, Ελβετία, Ισπανία, Μεγάλη Βρετανία, Χιλή
Palostar	Ινδία
Palzen	Ινδία
Vinaltro	Μεξικό
Viqet	Μεξικό
Vonaxi	Τουρκία

Βιβλιογραφία : Palonosetron hydrochloride

	τύπος	δημοσίευση
1932	εφημερίδα	Trissel LA, Zhang Y. Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. Int J Pharm Compound 2004 ; 8,5: 398-403.
1936	εφημερίδα	Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solusions. Ann Pharmacotherapy 2004 ; 38: 1608-1611.
1940	εφημερίδα	Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1950	εφημερίδα	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
1955	εφημερίδα	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
1975	εφημερίδα	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 235-237.
1976	εφημερίδα	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.
2009	εφημερίδα	Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2016	εφημερίδα	Xu QA, Trissel LA. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1998-2000.
2107	εφημερίδα	Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound 2006 ; 10: 234-236.
2179	εφημερίδα	Trusley C, Ben M, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 1: 82-85.
2196	εφημερίδα	Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration. Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2214	εφημερίδα	Ben M, Trusley C,Kupiec T.C, Trissel L.A. Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 6: 520-524.
2227	εφημερίδα	Trusley C, Ben M, Kupiec TC, Trissel LA. Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 2: 156-160.
2228	εφημερίδα	Kupiec T, Ben M, Trusley C, Trissel LA. Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. Int J Pharm Compound 2008 ; 12,2: 170-173.
2279	εφημερίδα	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2281	εφημερίδα	Ben M, Kupiec T, Trusley C, Trisel LA. Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 5: 460-462.
2286	εφημερίδα	Ben M, Trusley C, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 4: 368-371.
2312	εφημερίδα	Trissel L.A, Trusley C, Kupiec T.C, Ben M. Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration. Int J Pharm Compound 2009 ; 13, 1: 78-80.
3459	εφημερίδα	Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3928	εφημερίδα	Wu G, Yeung S, Chen F. Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride. Int J Pharm Compound 2017 ; 21, 1: 76-82.
3981	εφημερίδα	He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D. Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study EJHP 2017 ;24:162?166
4062	εφημερίδα	Wu George, Powers Dan, Yeung S, Chen F, Neelon K. Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection. Int J Pharm Compound 2018 ;22,1:76-85
4310	εφημερίδα	Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M. Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.

Mentions Légales